UNSPSC 51372316: Phenampromide

This classification denotes an opioid with the molecular formula C17H26N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0600L2M6EZ, chemically known as propionanilide, n-(1-methyl-2-piperidinoethyl)- but generally known as phenampromide, which bears US NIH Compound Identifier 8523. European Medicines Agency schedules Phenampromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09750MIG.

UNSPSC 51372316 Phenampromide is a Commodity code with minimal recent state and local procurement activity directly aligned to its nominal scope. The three most recent opportunities tagged to this code show a pronounced mismatch: Seminole County, Florida solicited naloxone and drug deactivation systems through an IFB; the Texas Health and Human Services Commission issued an RFI on direct-to-manufacturer prescription fulfillment programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administered by the Minnesota Department of Administration released an RFP for generic multi-source pharmaceuticals and over-the-counter products through authorized wholesalers. None of these procurements target phenampromide specifically, and the code appears to describe a distinct pharmaceutical compound rather than the broader pharmaceutical distribution, naloxone supply, or prescription-management programs these jurisdictions are actually buying. The issuing bodies span state health departments, county public health operations, and cooperative purchasing consortia serving multiple states, but the procurement activity itself does not reflect phenampromide demand.

Geographic activity is dispersed across Florida, Texas, Minnesota, and Oregon (through MMCAP participation), but the lack of phenampromide-specific solicitations suggests either that the code is rarely used by state and local buyers or that recent opportunities have been misclassified. The Seminole County naloxone procurement (IFB 60459723LAS, response deadline July 26, 2023) sought 1,900 units annually with quarterly deliveries; the Texas HHS RFI (HHS0017013, posted April 3, 2026) was exploratory market research on direct pharmaceutical contracting; and the MMCAP RFP (S1070000015802, due March 26, 2026) targeted established generic pharmaceuticals through three authorized drug wholesalers with awards effective July 1, 2026. State and local buyers pursuing pharmaceutical supply contracts should verify code assignment in any formal solicitation to confirm phenampromide is the actual commodity being sought rather than relying on recent activity under this code as a reliable signal of current demand.